Dapsone treatment of Pneumocystis carinii pneumonia in the acquired immunodeficiency sydrome

J. Mills, G. Leoung, I. Medina, P. C. Hopewell, W. T. Hughes, C. Wofsy

Research output: Contribution to journalArticlepeer-review

Abstract

All patients with the acquired immunodeficiency syndrome treated for their first episode of Pneumocystis carinii pneumonia at San Francisco General Hospital between 1 April 1985 and 15 July 1985 were evaluated for their response to treatment with dapsone (100 mg/day) by mouth for 21 days. Of 44 patients evaluated, 18 were eligible for the study. Of these 18 patients, the conditions of 7 of them worsened or failed to improve during treatment with dapsone and they were considered treatment failures. These patients were changed to standard therapy after 4 to 8 days of dapsone therapy. The remaining 11 patients (61%) improved within 3 to 10 days after dapsone therapy was started. Side effects of dapsone therapy were noted in 6 of 11 patients (of these 11 patients, 5 had a rash, 1 had a rash and abnormal liver enzymes, and 1 had abnormal liver enzymes), but in none of the patients were these side effects severe enough to require the cessation of medication. Based on comparison with historical controls, oral dapsone therapy alone appeared to be less effective than standard therapy or the combination of dapsone plus trimethoprim for P. carinii pneumonia in patients with acquired immunodeficiency syndrome.

Original languageEnglish (US)
Pages (from-to)1057-1060
Number of pages4
JournalAntimicrobial agents and chemotherapy
Volume32
Issue number7
DOIs
StatePublished - 1988

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Infectious Diseases

Fingerprint Dive into the research topics of 'Dapsone treatment of Pneumocystis carinii pneumonia in the acquired immunodeficiency sydrome'. Together they form a unique fingerprint.

Cite this